Skip to main content

Advertisement

SpringerLink
Log in

Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

The fatigue associated with five newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) (regorafenib, vandetanib, cabozantinib, lenvatinib, axitinib) is poorly understood. We conducted this systematic review to fully investigate the fatigue associated with these VEGFR-TKIs in cancer patients. Relevant studies of randomized controlled trials in cancer patients treated with the five VEGFR-TKIs were retrieved and a systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published until March 2017. Thirteen randomized controlled trials and 4395 patients were included. The current analysis suggested that the use of five newly approved VEGFR-TKIs increased the risk of all-grade fatigue (1.43; 95% CI 1.23–1.66; p < 0.00001) and high-grade (≥grade 3) fatigue (1.97; 95% CI1.44–2.70; p < 0.0001). On subgroup analysis, the risk ratio (RR) of all-grade fatigue varied significantly within drug type, but high-grade fatigue did not. The RR of all-grade and high-grade fatigue did not vary significantly according to cancer type, treatment line, and treatment duration. The risk of high-grade fatigue may vary with treatment duration, whereas all-grade fatigue may not. The available data suggest that the use of the five newly approved VEGFR-TKIs is associated with a significantly increased risk of fatigue in cancer patients. Physicians should be aware of this adverse effect and should monitor cancer patients receiving these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cook AM, Lesterhuis WJ, Nowak AK et al (2016) Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol 39:23–29

    Article  CAS  PubMed  Google Scholar 

  2. Ahn JS, Lee KH, Sun JM et al (2013) A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer 82(3):455–460

    Article  PubMed  Google Scholar 

  3. Arnold AM, Seymour L, Smylie M, National Cancer Institute of Canada Clinical Trials Group Study BR.20 et al (2007) Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25(27):4278–4284

    Article  CAS  PubMed  Google Scholar 

  4. Polimeni M, Gazzano E (2014) Is redox signaling a feasible target for overcoming multidrug resistance in cancer chemotherapy. Front Pharmacol 5:286

    Article  PubMed  PubMed Central  Google Scholar 

  5. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18

    Article  CAS  PubMed  Google Scholar 

  6. Zetter BR (1998) Angiogenesis and tumor metastasis. Annu Rev Med 49:407–424

    Article  CAS  PubMed  Google Scholar 

  7. Sharp A, Bhosle J, Abdelraouf F et al (2016) Development of molecularly targeted agents and immunotherapies in small cell lung cancer. Eur J Cancer 60:26–39

    Article  CAS  PubMed  Google Scholar 

  8. Minton O, Berger A, Barsevick A et al (2013) Cancer-related fatigue and its impact on functioning. Cancer 119(Suppl. 11):2124–2130

    Article  PubMed  Google Scholar 

  9. Pachman DR, Barton DL, Swetz KM et al (2012) Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol 30:3687–3696

    Article  PubMed  Google Scholar 

  10. National Comprehensive Cancer Network. NCCN clinical practiceguidelines in oncology. Cancer-related fatigue, Version 1.2009

  11. Ghatalia P, Je Y, Nguyen PL et al (2015) Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamyc in inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: a meta-analysis of randomized clinical trials. Crit Rev Oncol 94(1):136–145

    Article  Google Scholar 

  12. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269

    Article  PubMed  Google Scholar 

  13. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reportsof randomized clinical trials: is blinding necessary. Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  14. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123–137

    Article  PubMed  Google Scholar 

  15. DerSimonian R, Larid N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  16. Li J, Qin S, Xu R et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619–629

    Article  CAS  PubMed  Google Scholar 

  17. Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312

    Article  CAS  PubMed  Google Scholar 

  18. Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebo controlled phase 3 trial (GRID). Lancet 381(9863):295–302

    Article  CAS  PubMed  Google Scholar 

  19. Mir O, Brodowicz T, Italiano A et al (2016) Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17(12):1732–1742

    Article  CAS  PubMed  Google Scholar 

  20. Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66

    Article  CAS  PubMed  Google Scholar 

  21. Lee JS, Hirsh V, Park K et al (2012) Vandetanib versus placebo in patients with advanced non–small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase iii trial (ZEPHYR). J Clin Oncol 30(10):1114–1121

    Article  CAS  PubMed  Google Scholar 

  22. Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134–141

    Article  CAS  PubMed  Google Scholar 

  23. Leboulleux S, Bastholt L, Krause T et al (2012) Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13(9):897–905

    Article  CAS  PubMed  Google Scholar 

  24. Hsu C, Yang TS, Huo TI et al (2012) Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol 56(5):1097–1103

    Article  CAS  PubMed  Google Scholar 

  25. Elisei R, Schlumberger MJ, Müller SP et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639–3646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630

    Article  PubMed  Google Scholar 

  27. Kang YK, Yau T, Park JW et al (2015) Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 26(12):2457–2463

    PubMed  Google Scholar 

  28. Rini BI, Tomita Y, Melichar B et al (2016) Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. Clin Genitourin Cancer 14(6):499–503

    Article  PubMed  Google Scholar 

  29. Makita N, Iiri T (2013) Tyrosine kinase inhibitor-induced thyroid disorders: areview and hypothesis. Thyroid 23:151–159

    Article  CAS  PubMed  Google Scholar 

  30. Schutz FA, Je Y, Richards CJ et al (2012) Meta-analysis of random-ized controlled trials for the incidence and risk of treatment-relatedmortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871–877

    Article  CAS  PubMed  Google Scholar 

  31. Antoun S, Birdsell L, Sawyer MB et al (2010) Association of skeletal musclewasting with treatment with sorafenib in patients with advanced renalcell carcinoma: results from a placebo-controlled study. J Clin Oncol 28:1054–1060

    Article  CAS  PubMed  Google Scholar 

  32. Miyamoto Y, Yuki S, Shimokawa M et al (2016) A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402). J Clin Oncol 34(Supplement):15

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Southwest University for Nationalities, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan, 610041, People’s Republic of China

    Jing Li & Jian Gu

Authors
  1. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jing Li.

Ethics declarations

Funding

This work was supported by the Fundamental Research Funds for the Central Universities, Southwest University for Nationalities, 2017NZYQN29.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

For this type of study, formal consent is not required.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 232 kb)

Supplementary material 2 (DOC 63 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, J., Gu, J. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis . Int J Clin Oncol 22, 807–816 (2017). https://doi.org/10.1007/s10147-017-1167-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1167-1

Keywords

Search

Navigation